论文部分内容阅读
目的 研究肝硬化患者红细胞补体受体I型分子(Complement receptor type 1,CR1)密度相关基因多态性、数量表达及活性的变化。方法 采用PCR和Hind Ⅲ酶切技术测定红细胞CR1分子基因多态性,采用酶联法定量测定红细胞CR1分子的数量,采用红细胞天然免疫粘附功能实验测定红细胞CR1分子粘附活性。结果 肝硬化患者红细胞CR1分子密度相关基因多态性与正常人相比,差异无显著性意义(P>0.05),但其红细胞CR1分子的数量表达及活性明显低于正常健康人群(P<0.01),失代偿性乙肝后肝硬化患者的CR1分子数量明显低于代偿性乙肝后肝硬化患者(P<0.05),但肝功正常的肝硬化患者红细胞CR1分子数量与正常人比较无明显变化(P>0.05)。结论 肝硬化患者红细胞CR1分子数量表达及活性缺陷可能是后天因素引起;测定肝硬化患者红细胞CR1分子的数量对临床病情判断及发展预测有重要参考价值。
Objective To study the polymorphism, quantitative expression and activity of erythrocyte complement receptor type 1 (CR1) related genes in patients with liver cirrhosis. Methods The gene polymorphisms of CR1 in erythrocytes were determined by PCR and Hind Ⅲ digestion. The number of CR1 in erythrocytes was quantitatively determined by enzyme-linked immunosorbent assay (ELISA), and the adhesion activity of erythrocyte CR1 was determined by erythrocyte innate immunity adhesion assay. Results There was no significant difference in the polymorphism of erythrocyte CR1 between cirrhosis and normal controls (P> 0.05). However, the expression and activity of CR1 in erythrocytes were significantly lower than those in healthy controls (P <0.01) ), The number of CR1 molecules in patients with decompensated hepatitis B cirrhosis was significantly lower than those in patients with compensated hepatitis B cirrhosis (P <0.05). However, the number of CR1 molecules in erythrocytes of patients with normal liver function was not significantly different Change (P> 0.05). Conclusions The expression and activity of erythrocyte CR1 in patients with cirrhosis may be caused by acquired factors. The determination of the number of erythrocyte CR1 in patients with cirrhosis has important reference value for judging and predicting the clinical condition.